Researchers published in Nature Communications that engineered lipid vesicles can enhance gastrointestinal absorption of oral antibiotics while mitigating gut microbiome disruption. The study demonstrated that vesicle‑encapsulated antibiotics improved systemic drug exposure and reduced indices of dysbiosis compared with free drug formulations in preclinical models. The platform leverages nanoparticle delivery to balance efficacy and microbiome preservation, a dual objective with clear translational implications for oral antibiotic development. Authors and journal data indicate potential for lowering systemic doses and reducing collateral damage to commensal microbes, which could influence future formulation strategies and clinical trial designs.